Jeffrey Grice

Dr. Jeffrey Grice

Diamantina Institute
+1

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
TPTarl Prow
Tarl Prow
JGJeffrey Grice
Jeffrey Grice
LLLynlee L. Lin
Lynlee L. Lin
RFRokhaya Faye
Rokhaya Faye
MBMargaret Butler
Margaret Butler
Michael RobertsMichael Roberts
Michael Roberts

21 September 2017 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CNChristofori Nastiti
Christofori Nastiti
TPThellie Ponto
Thellie Ponto
EAEman Abd
Eman Abd
JGJeffrey Grice
Jeffrey Grice
Heather BensonHeather Benson
Heather Benson
Michael RobertsMichael Roberts
Michael Roberts
Nanosystems such as microemulsions (ME) and nanoemulsions (NE) offer considerable opportunities for targeted drug delivery to and via the skin. ME and NE are stable colloidal systems composed of oil and water, stabilised by a mixture of surfactants and cosurfactants, that have received particular interest as topical skin delivery systems. There is considerable scope to manipulate the formulation components and characteristics to achieve optimal bioavailability and minimal skin irritancy. This includes the incorporation of established chemical penetration enhancers to fluidize the stratum corneum lipid bilayers, thus reducing the primary skin barrier and increasing permeation. This review discusses nanosystems with utility in skin delivery and focuses on the composition and characterization of ME and NE for topical and transdermal delivery. The mechanism of skin delivery across the stratum corneum and via hair follicles is reviewed with particular focus on the influence of formulation.

1 April 2011 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Michael RobertsMichael Roberts
Michael Roberts
YDYuri Dancik
Yuri Dancik
TPTarl Prow
Tarl Prow
CTCamilla A. Thorling
Camilla A. Thorling
LLLynlee L. Lin
Lynlee L. Lin
WBWolfgang Becker
Wolfgang Becker

10 December 2014 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
HWHaolu Wang
Haolu Wang
CTCamilla A. Thorling
Camilla A. Thorling
XLXiaowen Liang
Xiaowen Liang
KBKim R. Bridle
Kim R. Bridle
JGJeffrey Grice
Jeffrey Grice
Michael RobertsMichael Roberts
Michael Roberts
Liver diseases, particularly viral hepatitis, cirrhosis and hepatocellular carcinoma, are common in clinical practice with high morbidity and mortality worldwide. Many substances for diagnostic imaging and therapy of liver diseases may have either severe adverse effects or insufficient effectiveness in vivo because of their nonspecific uptake. Therefore, by targeting the delivery of drugs into the liver or specific liver cells, drug efficiency may be largely improved. This review summarizes the up-to-date research progress focusing on nanoparticles targeting the liver for both diagnostic and therapeutic purposes. Targeting strategies, mechanisms of enhanced effects, and clinical applications of nanoparticles are discussed specifically. We believe that new targeting nanotechnology such as nanoprobes for multi-modality imaging and multifunctional nanoparticles would facilitate significant advancements in this active research area in the near future.

23 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SNSarika Namjoshi
Sarika Namjoshi
MDMaryam Dabbaghi
Maryam Dabbaghi
Michael RobertsMichael Roberts
Michael Roberts
JGJeffrey Grice
Jeffrey Grice
YOUSUF HUSSAIN MOHAMMEDYOUSUF HUSSAIN MOHAMMED
YOUSUF HUSSAIN MOHAMMED
In recent years, the “quality by design” (QbD) approach has been used for developing pharmaceutical formulations. This is particularly important for complex dosage forms such as topical semisolid products. The first step for developing a product using this efficient approach is defining the quality target product profile (QTPP), a list of quality attributes (QAs) that are required to be present in the final product. These quality attributes are affected by the ingredients used as well as manufacturing procedure parameters. Hence, critical material attributes (CMAs) and critical process parameters (CPPs) need to be specified. Possible failure modes of a topical semisolid product can be determined based on the physiochemical properties of ingredients and manufacturing procedures. In this review, we have defined and specified QTPP, QAs, CMAs and CPPs that are required for developing a topical semisolid product based on the QbD approach.

1 April 1998 in Gynecologic Oncology
Verified
Journal Article
Closed access
JGJeffrey Grice
Jeffrey Grice
MEMarit Ek
Marit Ek
BGBenjamin Greer
Benjamin Greer
WKWui-Jin Koh
Wui-Jin Koh
HMHoward G. Muntz
Howard G. Muntz
BGBarbara A. Goff
Barbara A. Goff